United States 114th Congress Status: Died 1 R cosponsors

HR 1849 — Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015

Last action — Referred to the Subcommittee on Health.

Track this bill free

No card. One bill, free forever — alerts when it moves.

  1. ✓
    Introduced
  2. ✓
    In Committee
  3. Died in session

This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.

This bill is no longer active — its legislative session has ended, so there is no live prognosis. It would have to be reintroduced in the current session to move again.

Summary

Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015 Amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to establish and implement a hereditary hemorrhagic telangiectasia (HHT, a genetic vascular bleeding disorder that causes abnormalities of the blood vessels) initiative to improve early detection, screening, and treatment of people who suffer from HHT, focusing on advancing HHT research and increasing physician and public awareness of HHT. Directs HHS to establish the HHT Coordinating Committee to develop and coordinate implementation of a plan to advance research and understanding of HHT, including by conducting or supporting research at the National Institutes of Health (NIH) and making recommendations regarding NIH research grants relating to HHT. Requires the Centers for Disease Control and Prevention to carry out activities with respect to HHT, including conducting surveillance and establishing an HHT resource center to provide comprehensive education on and disseminate information about HHT to health professionals, patients, industry, and the public. Requires the Centers for Medicare & Medicaid Services to award grants for HHT research, including an analysis of health care expenditures associated with untreated HHT and costs associated with preventable medical events among Medicare beneficiaries with HHT.

Bill Text

We don't have the full text on file for this bill yet.

Read HR 1849 on the official United States source →

Action History

  1. Referred to the Subcommittee on Health.

  2. Referred to the Subcommittee on Health.

  3. Referred to House Ways and Means

  4. Referred to House Energy and Commerce

  5. Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

  6. Introduced in House

Sponsors

Sponsorship breakdown

Export CSV (upgrade) →

1 sponsors · 0 co-sponsors · 546 not signed on

Sponsors (1)

Co-sponsors (0)

None.

Not signed on (546)

546 members have not signed on to this bill.

Show all 546 →

"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.

Whip count is in markup. Polling the chamber and every recorded vote this session. Only the first open is slow. It’s instant for you after this. Calling the roll · Tallying · Engrossing

Subjects

healthcare health-insurance
Cross-referencing the record. Reading this bill against every other bill in the corpus by meaning, not keywords. Only the first open is slow. It’s instant for you after this. Matching · Ranking · Engrossing

Frequently asked questions

What does HR 1849 do?
Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2015 Amends the Public Health Service Act to require the Department of Health and Human Services (HHS) to establish and implement a hereditary hemorrhagic telangiectasia (HHT, a genetic vascular bleeding disorder that causes abnormalities of the blood vessels) initiative to improve early detection, screening, and treatment of people who suffer from HHT, focusing on advancing HHT research and increasing physician and public awareness of HHT. Directs HHS to establish the HHT Coordinating Committee to develop and coordinate implementation of a plan to advance research and understanding of HHT, including by conducting or supporting research at the National Institutes of Health (NIH) and making recommendations regarding NIH research grants relating to HHT. Requires the Centers for Disease Control and Prevention to carry out activities with respect to HHT, including conducting surveillance and establishing an HHT resource center to provide comprehensive education on and disseminate information about HHT to health professionals, patients, industry, and the public. Requires the Centers for Medicare & Medicaid Services to award grants for HHT research, including an analysis of health care expenditures associated with untreated HHT and costs associated with preventable medical events among Medicare beneficiaries with HHT.
Who sponsors HR 1849?
HR 1849 is sponsored by Edward Royce (R).
What is the current status of HR 1849?
This bill died with 114th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
Where can I track HR 1849?
Track HR 1849 free on One Click Politics — get push/email alerts when it moves.

Make your voice heard on HR 1849

Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.

Find my representatives → Run a campaign

Stay ahead of HR 1849

Last checked for changes about 14 hours ago · updated continuously

One Click Politics tracks every bill in Congress and all 50 states.

Track this bill →